- Home
- CRDL
as 12-20-2024 4:00pm EST
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
| Founded: | 2017 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 125.7M | IPO Year: | N/A |
| Target Price: | $9.00 | AVG Volume (30 days): | 391.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.79 - $3.12 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cardiol Therapeutics Inc. News
CRDL Breaking Stock News: Dive into CRDL Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
Newsfile
a month ago
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
GlobeNewswire
a month ago
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
Newsfile
2 months ago
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
Newsfile
2 months ago
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
Newsfile
2 months ago
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
Newsfile
2 months ago
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
Newsfile
2 months ago
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Compare CRDL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRDL Cardiol Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.